PremiumCompany AnnouncementshVIVO Announces Director Update Amid Oncimmune Administration Strategic Acquisitions and Strong Pipeline Position Open Orphan Plc for Growth hVIVO plc to Announce 2024 Financial Results on April 10, 2025 PremiumCompany AnnouncementshVIVO Partners with Inhalon Biopharma for Innovative RSV Treatment Trial JPMorgan Reduces Stake in hVIVO PLC Below Minimum Threshold hVIVO PLC Sees Significant Shift in Voting Rights PremiumCompany AnnouncementshVIVO Advances hMPV Challenge Model With Successful Pilot Study hVIVO’s Landmark COVID-19 Study Published in Nature Communications hVIVO Clinches Major Contract for RSV Challenge Trials